癃畅颗粒治疗良性前列腺增生症的临床研究
|
摘要
目的:探讨癃畅颗粒治疗前列腺增生症的临床疗效。
方法:选择80例前列腺增生症患者随机分为两组,治疗组40例,口服癃畅颗粒,每次1袋,每天2次;对照组40例,口服前列康,每次4片,每日3次,1个月为1个疗程,两组均治疗1个疗程。对治疗前后临床症状、IPSS、QOL、最大尿流率、残余尿量、前列腺体积等指标进行对照分析。
结果:治疗组总有效率为78.4%,对照组总有效率为66.7%,经Ridit分析(P<0.05),两组疗效比较有显著性差异。治疗组疗后临床症状、IPSS、QOL、最大尿流率、残余尿量、前列腺体积均有明显改善,经t检验分析(P<0.05),治疗后两组疗效比较有显著性差异。
结论:癃畅颗粒治疗前列腺增生症疗效显著,且疗效优于前列康。
Objective: To observe the clinical effect on benign prostatic hyperplasia (BPH) treated by Long Chang Ke Li.Method: In clinical observation 80 patients were divided averagely into two groups at random: control group treated with Qian Lie Kang and treatment group with Long Chang Ke Li. The symptoms and sighs> the remark of IPSS and QOL、 residual urine volume and prostate volume were detected before treatment and after being treated for one month.Results: In the treatment group, the total effective rate was 78.4%.In the control group, the total effective rate was 66.7%. With Ridit test, the difference between the two groups was significant (P<0.05), which show that the effect of Long Chang Ke Li is better than the control group in treatment.Conclusion: The Long Chang Ke Li can obviously alleviate the symptoms and signs of the BPH. The results show that the effect of Long Chang Ke Li on the BPH was superior to that of Qian Lie Kang.
方法:选择80例前列腺增生症患者随机分为两组,治疗组40例,口服癃畅颗粒,每次1袋,每天2次;对照组40例,口服前列康,每次4片,每日3次,1个月为1个疗程,两组均治疗1个疗程。对治疗前后临床症状、IPSS、QOL、最大尿流率、残余尿量、前列腺体积等指标进行对照分析。
结果:治疗组总有效率为78.4%,对照组总有效率为66.7%,经Ridit分析(P<0.05),两组疗效比较有显著性差异。治疗组疗后临床症状、IPSS、QOL、最大尿流率、残余尿量、前列腺体积均有明显改善,经t检验分析(P<0.05),治疗后两组疗效比较有显著性差异。
结论:癃畅颗粒治疗前列腺增生症疗效显著,且疗效优于前列康。
Objective: To observe the clinical effect on benign prostatic hyperplasia (BPH) treated by Long Chang Ke Li.Method: In clinical observation 80 patients were divided averagely into two groups at random: control group treated with Qian Lie Kang and treatment group with Long Chang Ke Li. The symptoms and sighs> the remark of IPSS and QOL、 residual urine volume and prostate volume were detected before treatment and after being treated for one month.Results: In the treatment group, the total effective rate was 78.4%.In the control group, the total effective rate was 66.7%. With Ridit test, the difference between the two groups was significant (P<0.05), which show that the effect of Long Chang Ke Li is better than the control group in treatment.Conclusion: The Long Chang Ke Li can obviously alleviate the symptoms and signs of the BPH. The results show that the effect of Long Chang Ke Li on the BPH was superior to that of Qian Lie Kang.
引文
[1] Berry Sj. The development of human benign prostatic hyperplasia with age. J Urol, 1984, 132:474
[2] 夏同礼,孔祥田,苏晋伟等 我国成人良性前列腺增生症的发生与组织形态特征,[J].中华泌尿外科杂志,1994,8(2):49
[3] Chang HL, Char GYv Benign hypertrophy of prostate.ChinMed J, 1936, 50:1707
[4] McConnell JD. Epodemiology, etiology, pathphtsiology, and diagnosis of benign prostatic hyperplasia [A].In: Walsh PC, Retik AB, Vaughan ED, et al, eds. Campbell's Urology[M].7th.Philadelphia:Saunders, 1998:1429
[5] Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hyperplasisin the community.The Lancet, 1991, 338:469
[6] 顾方六,山岗志,王通生等 北京城乡良性前列腺增生发病的差异[J].中华泌尿外科杂志,1995,16(7):387
[7] Walsh PC. Benign prostatic hyperplasia. In:Walsh PC, Retik AB, Stamey TA, et al (eds). Campbell's Urology, Vol 1, 6th ed, Philadephia, WB Saunders Company, 1992:1009
[8] Guess HA. Benign prostatic hyperplasia antecedents and natural history. Epidemiologic Review, 1992, 14:131
[9] 顾方六.重视良性前列腺增生的研究[J].中华医学杂志,1994,74(1):3
[10] 夏同礼,孔祥田,苏晋伟等 我国成人良性前列腺增生的发生与组织形态特征[J].中华泌尿外科杂志,1993,14:415
[11] 夏同礼.我国成年人前列腺增生与组织形态学特征[J].中华泌尿外科杂志,1993,14(6):415
[12] WU JP, Gu FL. The prostate 41-65 years post castration, an analysis of 26 ennuchs. ChinMed J, 1987, 100:271
[13] WU JP, Gu FL. The prostate in ennuchs. In:Smith PH, Pavone Macaluso M (eds) .Urological oncology.New York, Willey-Liss, 1991:169
[14] Wilson JD. The Pathogenesis of benign prostatic hyperplasia. Am J Med, 1980, 68:745
[15] GriffithsK, Lee C. Hormones, growth factors and benign prostatiic hyperplasia. In proceedings of the international consultation of benign prostatic hyperplasia. Cocket ATK, et al. SCI Paris.pp25
[16] Collins AT, Zhimign B, Gilmore K, et al. Androgen and oestrogen responsuveness of stromal cellls derived fron the human yperplastic prostate: oestrogen regulation of the androgen receptor. J Endocrine, 1994, 143:269
[17] Trachtenberg J, Hick L, Walsh PC. Androgen and oestrogen receptor content in spontaneous and experimentally induced canine prostatic hyperplasia.J Clin Invest, 1980, 65:1051
[18] Ricciardelli C, Horsfall DJ, Sykes PJ. Effects of oestradiol-17β and 5a-dihydrotestosterone on guinea-pig prostate smooth muscle cell proliferation and steroid recptor expression incitro. J Endocrine, 1994, 140:373
[19] 鲍镇美.细胞凋亡[J].中华泌尿外科杂志,1998,19:751
[20] Green DR.Apoptotic pathway: the roads to ruin.Cell, 1998, 94:695
[21] Tamm I, Wang Y, Sausville E, et al. IAP family protein surviving inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspaseand anticancer drugs.Cancer Res, 1998, 58:5315
[22] Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-deathprotease.Nature, 1997, 188:100
[23] Marcelli M, Cunning ham GR, Walkup M, et al. Signal pathway activated during apoptosis of the prostate cancer cell lone LNC a P: Over expression of Caspase 7 as a new gene therapy strategy for prostate cancer. Cancer Res, 1999, 59:382
[24] 邓方明,顾方六,夏同礼等 人良性前列腺增生细胞增殖和凋亡状态的研究[J].中华外科杂志,1996,34(10):620
[25] 王建业 主编 前列腺疾病理论与临床实践 北京出版社 2002年第1版
[26] Chang S, Chang LWK. Interaction between prostatic fibroblast and epithlial cells in culture: role of androgen. Endocrionlogy, 1989, 125:2719
[27] Davies P, Eaton CL. Regulation of prostate growth. Jcndocrinol, 1991, 131:5
[28] Morris GL, Dodd JG. Epidermal growth factor mRNA levels in human prostate and cell lines. J Urol, 1990, 143:1272
[29] Gregory H, Wollshire IR, Kavanagh JP, et al. Epidermal growth factor concentrations in prostatic hyperplasia. ClinSic, 1986, 70:359
[30] Davies P, Eaton CL. Binding of EGF by human normal, hypertrophic and carcinomaous prostate. The Prostate, 1989, 14:133
[31] 张学军,马腾骧,董克权等 用逆转录聚合酶链式反应检测转化生长因子-a在人良性前列腺增生中的表达[J].中华泌尿外科杂志,1993,14:284
[32] Chung Lee. Transforming growth factor a: a potentical growth regulator in prostatic carcionoma. Molecular and cell biology of prostate cancer. Karr JP. (edi) Plenum Press. New York.1991:147
[33] 邓方明,夏同礼,顾方六 多肽生长因子与良性前列腺增生[J].中华泌尿外科杂志,1994,15(6):223
[34] Folkman J, ShingY. Angiogenesis.J Biol Chem, 1992, 267:10931
[35] Campbell SC. Advances in angiogenesis reasearch: relevance to urological oncology. J Urol, 1997, 158:1663
[36] Deering ME, Bigler SA, Brown M, et al. Microvascularity in benign prostatic hyperplasia. Prostate, 1995, 26:111
[37] Weinartner K, Ben Sasson SA, Stewart R, et al. Endothlial cell proliferation activity in BPH and prostate cancer, an in vitro model forassessment,J Urol, 1998, 159:165
[38] 章咏裳.前列腺增生症药物治疗进展[J].临床泌尿外科杂志,1998,13(6):243
[39] Kirby RS. The pharmacological management of benign prostatic hyperplasia. Churchill Medical Communication, 1993:47
[40] Degerout LJ. Androgen physiology. Endocrinology. Vol 3, 3rd Ed, W.B. Saunders Company, 1995:2330
[41] 鲍镇美.良性前列腺增生的药物治疗[J].中华泌尿外科杂志,1996,17(7):387
[42] Rittmaster RS. Evidence for atrophy and apoptosisin the ventral prostate of rats given the 5a-reductase inhibitor Finasteride. Endicrinology, 1995, 130:741
[43] 鲍镇美.良性前列腺增生的药物治疗 [J].中华老年医学杂志,1997,16 (4):67
[44] Cohen Sm. Comprison of the effects of new specific azasteroid inhibitors of steroid 5a-reductase on canine hyperplastic prostate: suppression of prostatic DTH correctated with prostate repression. J Urol, 1995, 154:303
[45] Reddy PK, Wasserman NA, Gfameda F, Casfaneda-Zuniga WR: Balloon dilatation of the Prostate for treatment of benign hyperplasia.Urol Clin North Am, 1998, 15:529
[46] Walsh PC. Treatment of BPH.N Eng J Med, 1996, 335:586
[47] Reddy PK, Wasserman NA, Berg P ZHang G, Kapoor DA: Patient selection predicts out-come following ballon dilatation of Prostate [abstract], J Urol, 1991, 145:362.
[48] Fabian KM: The intraprostatic partial catheter (urologial spiral) in German. Urology[A]1980, 19:236
[49] Kaplan SA, Te Al. Transurethral electrivaporization of the prostate:anovel method for treating men with benign prostatic hyperplasia. Urollgy, 1995, 45:566
[50] 张锡君.对老年前列腺肥大防治的体会[J].中医杂志,1986,27(5):330
[51] 祁公任,陈涛 前列腺增生症中医病机证治观[J].江苏中医,1998,19(11):16
[52] 王天明.通闭汤治疗前列腺增生症120例[J].新中医,2002,34(11):58
[53] 陈洪延.补气升提法治疗前列腺增生症120例[J].山东中医杂志,2001,20(7):406
[54] 樊学中.软坚散结化瘀降蚀清热利湿法治疗前列腺增生症217例[J].新中医,1999,31(12):26
[55] 李位安.补阳还五汤加味治疗前列腺增生症70例[J].中医杂志,2002,43(1):49
[56] 王国斌.保元复春磁药贴治疗前列腺增生症临床研究,中医研究,1999,12(5):25
[57] 武义华.中药离子导入治疗前列腺增生症疗效观察[J].陕西中医函授,1998,14(4) :31
[58] 樊学忠.前列栓治疗前列腺增生症疗效观察,河南中医,2002,22(4):28
[2] 夏同礼,孔祥田,苏晋伟等 我国成人良性前列腺增生症的发生与组织形态特征,[J].中华泌尿外科杂志,1994,8(2):49
[3] Chang HL, Char GYv Benign hypertrophy of prostate.ChinMed J, 1936, 50:1707
[4] McConnell JD. Epodemiology, etiology, pathphtsiology, and diagnosis of benign prostatic hyperplasia [A].In: Walsh PC, Retik AB, Vaughan ED, et al, eds. Campbell's Urology[M].7th.Philadelphia:Saunders, 1998:1429
[5] Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hyperplasisin the community.The Lancet, 1991, 338:469
[6] 顾方六,山岗志,王通生等 北京城乡良性前列腺增生发病的差异[J].中华泌尿外科杂志,1995,16(7):387
[7] Walsh PC. Benign prostatic hyperplasia. In:Walsh PC, Retik AB, Stamey TA, et al (eds). Campbell's Urology, Vol 1, 6th ed, Philadephia, WB Saunders Company, 1992:1009
[8] Guess HA. Benign prostatic hyperplasia antecedents and natural history. Epidemiologic Review, 1992, 14:131
[9] 顾方六.重视良性前列腺增生的研究[J].中华医学杂志,1994,74(1):3
[10] 夏同礼,孔祥田,苏晋伟等 我国成人良性前列腺增生的发生与组织形态特征[J].中华泌尿外科杂志,1993,14:415
[11] 夏同礼.我国成年人前列腺增生与组织形态学特征[J].中华泌尿外科杂志,1993,14(6):415
[12] WU JP, Gu FL. The prostate 41-65 years post castration, an analysis of 26 ennuchs. ChinMed J, 1987, 100:271
[13] WU JP, Gu FL. The prostate in ennuchs. In:Smith PH, Pavone Macaluso M (eds) .Urological oncology.New York, Willey-Liss, 1991:169
[14] Wilson JD. The Pathogenesis of benign prostatic hyperplasia. Am J Med, 1980, 68:745
[15] GriffithsK, Lee C. Hormones, growth factors and benign prostatiic hyperplasia. In proceedings of the international consultation of benign prostatic hyperplasia. Cocket ATK, et al. SCI Paris.pp25
[16] Collins AT, Zhimign B, Gilmore K, et al. Androgen and oestrogen responsuveness of stromal cellls derived fron the human yperplastic prostate: oestrogen regulation of the androgen receptor. J Endocrine, 1994, 143:269
[17] Trachtenberg J, Hick L, Walsh PC. Androgen and oestrogen receptor content in spontaneous and experimentally induced canine prostatic hyperplasia.J Clin Invest, 1980, 65:1051
[18] Ricciardelli C, Horsfall DJ, Sykes PJ. Effects of oestradiol-17β and 5a-dihydrotestosterone on guinea-pig prostate smooth muscle cell proliferation and steroid recptor expression incitro. J Endocrine, 1994, 140:373
[19] 鲍镇美.细胞凋亡[J].中华泌尿外科杂志,1998,19:751
[20] Green DR.Apoptotic pathway: the roads to ruin.Cell, 1998, 94:695
[21] Tamm I, Wang Y, Sausville E, et al. IAP family protein surviving inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspaseand anticancer drugs.Cancer Res, 1998, 58:5315
[22] Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-deathprotease.Nature, 1997, 188:100
[23] Marcelli M, Cunning ham GR, Walkup M, et al. Signal pathway activated during apoptosis of the prostate cancer cell lone LNC a P: Over expression of Caspase 7 as a new gene therapy strategy for prostate cancer. Cancer Res, 1999, 59:382
[24] 邓方明,顾方六,夏同礼等 人良性前列腺增生细胞增殖和凋亡状态的研究[J].中华外科杂志,1996,34(10):620
[25] 王建业 主编 前列腺疾病理论与临床实践 北京出版社 2002年第1版
[26] Chang S, Chang LWK. Interaction between prostatic fibroblast and epithlial cells in culture: role of androgen. Endocrionlogy, 1989, 125:2719
[27] Davies P, Eaton CL. Regulation of prostate growth. Jcndocrinol, 1991, 131:5
[28] Morris GL, Dodd JG. Epidermal growth factor mRNA levels in human prostate and cell lines. J Urol, 1990, 143:1272
[29] Gregory H, Wollshire IR, Kavanagh JP, et al. Epidermal growth factor concentrations in prostatic hyperplasia. ClinSic, 1986, 70:359
[30] Davies P, Eaton CL. Binding of EGF by human normal, hypertrophic and carcinomaous prostate. The Prostate, 1989, 14:133
[31] 张学军,马腾骧,董克权等 用逆转录聚合酶链式反应检测转化生长因子-a在人良性前列腺增生中的表达[J].中华泌尿外科杂志,1993,14:284
[32] Chung Lee. Transforming growth factor a: a potentical growth regulator in prostatic carcionoma. Molecular and cell biology of prostate cancer. Karr JP. (edi) Plenum Press. New York.1991:147
[33] 邓方明,夏同礼,顾方六 多肽生长因子与良性前列腺增生[J].中华泌尿外科杂志,1994,15(6):223
[34] Folkman J, ShingY. Angiogenesis.J Biol Chem, 1992, 267:10931
[35] Campbell SC. Advances in angiogenesis reasearch: relevance to urological oncology. J Urol, 1997, 158:1663
[36] Deering ME, Bigler SA, Brown M, et al. Microvascularity in benign prostatic hyperplasia. Prostate, 1995, 26:111
[37] Weinartner K, Ben Sasson SA, Stewart R, et al. Endothlial cell proliferation activity in BPH and prostate cancer, an in vitro model forassessment,J Urol, 1998, 159:165
[38] 章咏裳.前列腺增生症药物治疗进展[J].临床泌尿外科杂志,1998,13(6):243
[39] Kirby RS. The pharmacological management of benign prostatic hyperplasia. Churchill Medical Communication, 1993:47
[40] Degerout LJ. Androgen physiology. Endocrinology. Vol 3, 3rd Ed, W.B. Saunders Company, 1995:2330
[41] 鲍镇美.良性前列腺增生的药物治疗[J].中华泌尿外科杂志,1996,17(7):387
[42] Rittmaster RS. Evidence for atrophy and apoptosisin the ventral prostate of rats given the 5a-reductase inhibitor Finasteride. Endicrinology, 1995, 130:741
[43] 鲍镇美.良性前列腺增生的药物治疗 [J].中华老年医学杂志,1997,16 (4):67
[44] Cohen Sm. Comprison of the effects of new specific azasteroid inhibitors of steroid 5a-reductase on canine hyperplastic prostate: suppression of prostatic DTH correctated with prostate repression. J Urol, 1995, 154:303
[45] Reddy PK, Wasserman NA, Gfameda F, Casfaneda-Zuniga WR: Balloon dilatation of the Prostate for treatment of benign hyperplasia.Urol Clin North Am, 1998, 15:529
[46] Walsh PC. Treatment of BPH.N Eng J Med, 1996, 335:586
[47] Reddy PK, Wasserman NA, Berg P ZHang G, Kapoor DA: Patient selection predicts out-come following ballon dilatation of Prostate [abstract], J Urol, 1991, 145:362.
[48] Fabian KM: The intraprostatic partial catheter (urologial spiral) in German. Urology[A]1980, 19:236
[49] Kaplan SA, Te Al. Transurethral electrivaporization of the prostate:anovel method for treating men with benign prostatic hyperplasia. Urollgy, 1995, 45:566
[50] 张锡君.对老年前列腺肥大防治的体会[J].中医杂志,1986,27(5):330
[51] 祁公任,陈涛 前列腺增生症中医病机证治观[J].江苏中医,1998,19(11):16
[52] 王天明.通闭汤治疗前列腺增生症120例[J].新中医,2002,34(11):58
[53] 陈洪延.补气升提法治疗前列腺增生症120例[J].山东中医杂志,2001,20(7):406
[54] 樊学中.软坚散结化瘀降蚀清热利湿法治疗前列腺增生症217例[J].新中医,1999,31(12):26
[55] 李位安.补阳还五汤加味治疗前列腺增生症70例[J].中医杂志,2002,43(1):49
[56] 王国斌.保元复春磁药贴治疗前列腺增生症临床研究,中医研究,1999,12(5):25
[57] 武义华.中药离子导入治疗前列腺增生症疗效观察[J].陕西中医函授,1998,14(4) :31
[58] 樊学忠.前列栓治疗前列腺增生症疗效观察,河南中医,2002,22(4):28